Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06372210 · ClinicalTrials.gov registry record · NA
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
A NA study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT06372210 is a NA study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 54 participants.
The verdict
NCT06372210, a NA study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
Interventions
- DRUG Placebo IEM tablet
- DRUG Abilify MyCite®
- DEVICE D-Tect Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2023-07-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06372210
The ClinicalTrials.gov registry entry for NCT06372210 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo IEM tablet is the first listed.
NCT06372210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06372210 about?
NCT06372210 is a clinical study titled "A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion". The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
What is the current status of trial NCT06372210?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2023-06-26. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT06372210?
The interventions under investigation include: Placebo IEM tablet (DRUG), Abilify MyCite® (DRUG), D-Tect Patch (DEVICE).
Who is sponsoring clinical trial NCT06372210?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.